We use artificial intelligence (AI) to empower our scientific team to reveal new insights from data, helping to accelerate the discovery and development of new cancer therapies.
We have proven our success
The Cancerappy Platform has generated all the drug programs in our portfolio, focusing both on the validation of new targets and on groups of compounds such as PROTACs and nanotechnology, in close collaboration with innovative academic centers.
CancerAppy is a biotech specialized in the field of cancer research, focused on the discovery and development of new therapeutic targets, based on its own artificial intelligence methodology
Cancer: a global problem
Cancer is a global problem and the identification of novel therapies is an urgent need. Unfortunately, drug development is a long lasting and expensive process with a high risk of failure.
Incorporation of targeted therapies challenge physicians and healthcare providers to adapt their systems to provide an easy and sustainable access to personalize medicine.
Better medicines for a personalized care
CancerAppy aims to solve this problem by reducing the risk of drug development, discovering and developing new, more effective and less toxic therapies.
We combine high scientific knowledge in biology, in chemistry,
in computer science, with rapid validation in the laboratory, and
always with the objective of solving a clinical need.
Our style: Where science meets artificial intelligence
Our team at CancerAppy is highly diversified, with practical experience, profound knowledge and subject matter expertise in oncology research, patient care and computer science. This enables us to provide cutting edge solutions, using science and artificial intelligence, at a global scale to hospitals, academic institutions, pharmaceutical companies and a wide range of players involved in patient care and cancer research.
Our AI-driven approach has allowed us to discover and begin developing promising cancer drug programs.
Thanks to our deep knowledge and expertise in oncology and AI, we use a massive amount of multimodal data in our state-of-the-art AI algorithms, helping to identify new therapeutic targets, identify lead compounds, and determine the mechanism of action of a given compound. as well as possible drug combinations.
We would be happy to talk to you.
Latest news about CancerAppy…
April 20th. We are going to attend the 19th Annual Anglonordic Life Science Conference.Meet us to discuss face to face about our latest works: CA04 first-in-class monoclonal antibody, CA05 first-in-class kinase inhibitor and CA07 novel PROTAC.We can’t wait to hear...
Cancerappy, together with UCLM, has been awarded the grant from the CCP21 program for the development of nanomedicines (nanoPROTACs), with a total budget of €757,000 and a project duration of 3 years.
Artificial intelligence (AI) has the potential to revolutionize the drug discovery process by accelerating the identification of novel drug candidates and reducing the time and cost of drug development. In recent years, there has been a surge of interest in applying...